TP53 and hepatocellular carcinoma: Sorafenib suppresses cell invasion and cell proliferation in hepatocellular carcinoma HepG2 and Huh-7 cells by up-regulating p53 and Forkhead box M1 transcription factor expressions, resulting in the inhibition of matrix metalloproteinase 2 and Ki-67 expression [74].